Company intelligence / Profile preview

Alpha Biopharmaceuticals

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Alpha Biopharmaceuticals is a clinical-stage biotechnology company focused on the development of targeted oncology therapeutics. The company's lead program is a next-generation CDK4/6 inhibitor designed to offer improved efficacy and a better safety profile compared to existing treatments for hormone receptor-positive, HER2-negative breast cancer. By leveraging its expertise in medicinal chemistry, Alpha Biopharmaceuticals aims to address resistance mechanisms in cancer and provide new options for patients with advanced solid tumors. The company is currently advancing its pipeline through mid-stage clinical trials while exploring combination therapies with other standard-of-care agents.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Alpha Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha Biopharmaceuticals.

Explore the full profile